| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 7 |
| 1 | TACROLIMUS | 6 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 6 |
| 3 | TACROLIMUS OINTMENT 0.1% | 6 |
| 4 | PACLITAXEL | 5 |
| 5 | TOPOTECAN | 5 |
| 6 | CISPLATIN | 3 |
| 7 | ETOPOSIDE | 3 |
| 8 | IPILIMUMAB | 3 |
| 9 | DURVALUMAB | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PLATINUM | 2 | 0.0038 |
| 1 | TOPOTECAN | 5 | 0.0008 |
| 2 | EVEROLIMUS TABLETS | 2 | 0.0001 |
| 3 | DURVALUMAB | 2 | 0.0001 |
| 4 | PEGFILGRASTIM | 1 | 0.0001 |
| 5 | IPILIMUMAB | 3 | 0.0001 |
| 6 | BEVACIZUMAB | 7 | 0.0001 |
| 7 | PACLITAXEL | 5 | 0.0000 |
| 8 | HUMAN IMMUNOGLOBULIN G | 1 | 0.0000 |
| 9 | TACROLIMUS OINTMENT 0.1% | 6 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 1 | Topoisomerase Inhibitor [EPC] | 6 | 0.0001 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 3 | 0.0001 |
| 3 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 7 | 0.0000 |
| 5 | Microtubule Inhibitor [EPC] | 5 | 0.0000 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2 | 0.0000 |
| 7 | Platinum-based Drug [EPC] | 3 | 0.0000 |
| 8 | Leukocyte Growth Factor [EPC] | 1 | 0.0000 |
| 9 | Kinase Inhibitor [EPC] | 2 | 0.0000 |